NOVARTIS ACQUIRES 75.4 PERCENT OUTSTANDING SHARES OF NEUTEC

Novartis announced that it has acquired or received valid acceptances for 75.4 per cent of the outstanding shares in NeuTec Pharma plc and has declared its offer for the UK biopharmaceutical company unconditional in all respects. This will allow for the delisting of NeuTec's shares and completing the acquisition.
Pharmabiz